Efficacy of lifestyle interventions in physical health management of patients with severe mental illness

被引:0
作者
Fernando Chacón
Fernando Mora
Alicia Gervás-Ríos
Inmaculada Gilaberte
机构
[1] Lilly SA,Clinical Research Department
[2] Hospital Infanta Leonor,Servicio de Psiquiatría
来源
Annals of General Psychiatry | / 10卷
关键词
Schizophrenia; Metabolic Syndrome; Metformin; Bipolar Disorder; Smoking Cessation;
D O I
暂无
中图分类号
学科分类号
摘要
Awareness of the importance of maintaining physical health for patients with severe mental illnesses has recently been on the increase. Although there are several elements contributing to poor physical health among these patients as compared with the general population, risk factors for cardiovascular disease such as smoking, diabetes mellitus, hypertension, dyslipidemia, metabolic syndrome, and obesity are of particular significance due to their relationship with mortality and morbidity. These patients present higher vulnerability to cardiovascular risk factors based on several issues, such as genetic predisposition to certain pathologies, poor eating habits and sedentary lifestyles, high proportions of smokers and drug abusers, less access to regular health care services, and potential adverse events during pharmacological treatment. Nevertheless, there is ample scientific evidence supporting the benefits of lifestyle interventions based on diet and exercise designed to minimize and reduce the negative impact of these risk factors on the physical health of patients with severe mental illnesses.
引用
收藏
相关论文
共 527 条
[31]  
Piatt EE(2005)Schizophrenia and increased risks of cardiovascular disease Am Heart J 150 1115-1262
[32]  
Munetz MR(2009)Mortality in patients with schizophrenia Lancet 374 1591-S9
[33]  
Ritter C(2009)A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies Arch Gen Psychiatry 66 1253-S33
[34]  
Dickey B(2009)Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies J Am Pharm Assoc 49 S3-1589
[35]  
Normand SL(2009)The management and treatment of hypertension Clin Cornerstone 9 S27-793
[36]  
Weiss RD(2007)Update on dyslipidemia J Clin Endocrinol Metab 92 1581-1139
[37]  
Drake RE(2006)Emerging therapeutic strategies for obesity Endocr Rev 27 779-135
[38]  
Azeni H(2006)Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004 Psychiatr Serv 57 1132-769
[39]  
Hasnain M(2006)Association between antipsychotic drugs and diabetes Diabetes Obes Metab 8 125-21
[40]  
Vieweg WV(2008)Olanzapine: review of safety 2008 Expert Opin Drug Saf 7 761-26